Kidney NGAL is a novel early marker of acute injury following transplantation
Top Cited Papers
- 1 June 2006
- journal article
- Published by Springer Nature in Pediatric Nephrology
- Vol. 21 (6), 856-863
- https://doi.org/10.1007/s00467-006-0055-0
Abstract
Acute kidney injury secondary to ischemia–reperfusion in renal allografts often results in delayed graft function. We tested the hypothesis that expression of neutrophil gelatinase-associated lipocalin (NGAL) is an early marker of acute kidney injury following transplantation. Sections from paraffin-embedded protocol biopsy specimens obtained at approximately one hour of reperfusion after transplantation of 13 cadaveric (CAD) and 12 living-related (LRD) renal allografts were examined by immunohistochemistry for expression of NGAL. The staining intensity was correlated with cold ischemia time, peak post-operative serum creatinine, and dialysis requirement. There were no differences between the LRD and CAD groups in age, gender or preoperative serum creatinine. Using a scoring system of 0 (no staining) to 3 (most intense staining), NGAL expression was significantly increased in CAD specimens (2.3±0.8 versus 0.8±0.7 in LRD, pR=0.87, pR=0.86, p<0.001). Four patients developed delayed graft function requiring dialysis during the first week posttransplantation; all of these patients displayed the most intense NGAL staining in their first protocol biopsies. We conclude that NGAL staining intensity in early protocol biopsies represents a novel predictive biomarker of acute kidney injury following transplantation.Keywords
This publication has 51 references indexed in Scilit:
- Acute renal failureThe Lancet, 2005
- Acute renal failureThe Lancet, 2005
- Amelioration of Ischemic Acute Renal Injury by Neutrophil Gelatinase-Associated LipocalinJournal of the American Society of Nephrology, 2004
- Early detection of acute renal failure by serum cystatin CKidney International, 2004
- Differential gene expression following early renal ischemia/reperfusionKidney International, 2003
- Delayed Graft Function: State of the Art, November 10–11, 2000. Summit Meeting, Scottsdale, Arizona, USAAmerican Journal of Transplantation, 2001
- A RANDOMIZED MULTICENTER TRIAL OF THE ANTI-ICAM-1 MONOCLONAL ANTIBODY (ENLIMOMAB) FOR THE PREVENTION OF ACUTE REJECTION AND DELAYED ONSET OF GRAFT FUNCTION IN CADAVERIC RENAL TRANSPLANTATIONTransplantation, 1999
- Early graft function and patient survival following cadaveric renal transplantationKidney International, 1999
- Delayed graft function of more than six days strongly decreases long-term survival of transplanted kidneysKidney International, 1998
- Treatment of acute renal failureKidney International, 1998